| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 151, 69-80, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
ML Schmidt, VM Lee, M Forman, TS Chiu and JQ Trojanowski
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA.
Here we describe the initial characterization of a 100-kd protein recognized by four new monoclonal antibodies that reveal abundant and unique plaque-like lesions throughout gray matter of Alzheimer's disease brains. This 100-kd protein and these new plaque-like lesions were identified by four monoclonal antibodies raised to immunogens extracted from Alzheimer's disease neurofibrillary abnormalities. However, these antibodies did not recognize hyperphosphorylated tau in Western blots or neurofibrillary lesions by immunohistochemistry. As all of these antibodies displayed similar properties, one, AMY117, was used to characterize the new plaque-like lesions in detail. These studies demonstrated that AMY117-positive plaques were not visualized by amyloid stains and never co-localized with A beta deposits, although AMY117-positive and A beta-positive lesions frequently occurred in the same cortical and subcortical gray matter regions. Abundant AMY117- positive plaques were found in the brains of all 32 sporadic Alzheimer's disease patients and all 6 elderly Down's syndrome subjects. Although AMY117-positive plaques also were seen in the brains of nondemented patients with numerous A beta deposits. AMY117-positive plaques were rare or absent in the brains of other elderly controls and patients with other neurodegenerative or neuropsychiatric disorders. We conclude that the AMY117-positive plaques described here for the first time are major lesions of the Alzheimer's disease brain. Thus, it will be important to elucidate the role played by the 100-kd protein and the AMY117 plaques in the etiology and pathogenesis of Alzheimer's disease.
This article has been cited by other articles:
 |
|
 |
|
  L. Soderberg, H. Kakuyama, A. Moller, A. Ito, B. Winblad, L. O. Tjernberg, and J. Naslund Characterization of the Alzheimer's Disease-associated CLAC Protein and Identification of an Amyloid {beta}-Peptide-binding Site J. Biol. Chem., January 14, 2005; 280(2): 1007 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kowa, T. Sakakura, Y. Matsuura, T. Wakabayashi, D. M.A. Mann, K. Duff, S. Tsuji, T. Hashimoto, and T. Iwatsubo Mostly Separate Distributions of CLAC- versus A{beta}40- or Thioflavin S-Reactivities in Senile Plaques Reveal Two Distinct Subpopulations of {beta}-Amyloid Deposits Am. J. Pathol., July 1, 2004; 165(1): 273 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Lippa, M. L. Schmidt, L. E. Nee, T. Bird, D. Nochlin, C. Hulette, H. Mori, V. M.- Y. Lee, and J. Q. Trojanowski AMY plaques in familial AD: Comparison with sporadic Alzheimer's disease Neurology, January 11, 2000; 54(1): 100 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Lemere, T. J. Grenfell, and D. J. Selkoe The AMY Antigen Co-Occurs with A{beta} and Follows Its Deposition in the Amyloid Plaques of Alzheimer's Disease and Down Syndrome Am. J. Pathol., July 1, 1999; 155(1): 29 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sasaki, R. Fukatsu, K. Tsuzuki, Y. Hayashi, T. Yoshida, N. Fujii, T. Koike, I. Wakayama, R. Yanagihara, R. Garruto, et al. Advanced Glycation End Products in Alzheimer's Disease and Other Neurodegenerative Diseases Am. J. Pathol., October 1, 1998; 153(4): 1149 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Conti, R. Raghupathi, J. Q. Trojanowski, and T. K. McIntosh Experimental Brain Injury Induces Regionally Distinct Apoptosis during the Acute and Delayed Post-Traumatic Period J. Neurosci., August 1, 1998; 18(15): 5663 - 5672. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
